News Evotec SE CBOE

Stocks

0IRF

DE0005664809

Biotechnology & Medical Research

Market Closed - CBOE 11:30:00 2026-09-11 EDT			5-day change	1st Jan Change
3.217 ^EUR	0.00%		0.00%	-40.37%

09-09	Evotec Initiates Phase 1 Trial of Potential Smallpox, Mpox Treatment	MT
09-09	Evotec Commences Early-stage Study of Potential Orthopoxvirus Therapy	MT

All News

Mentions Relevance

09-09	Evotec Initiates Phase 1 Trial of Potential Smallpox, Mpox Treatment	MT
09-09	Evotec Commences Early-stage Study of Potential Orthopoxvirus Therapy	MT
09-09	Just – Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical Studies	EQ
09-02	Evotec, Plectonic Launch Research Collaboration on New T-Cell Approaches for Solid Tumors	MT
09-02	Evotec, Plectonic Biotech Partner on Research of Novel Immunotherapy for Solid Tumors	MT
09-02	Evotec SE And Plectonic Biotech Enter Research Collaboration To Explore New Generation Of T-Cell-Engaging Approaches For Solid Tumors	CI
09-02	Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors	EQ
08-13	Evotec's final first-half results once again spook investors	DP
08-13	Evotec SE Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-13	Evotec SE : Gets a Buy rating from RBC	ZD
08-13	Evotec : Half-year report 2026, PDF (H1 Report 2026 English)	PU
08-13	Evotec : Half-year report 2026, PDF (Interim Statement H1 2026 English)	PU
08-13	Evotec Se Announces Camilla Macapili Languille Step Down as Supervisory Board, Effective August 7, 2026	CI
08-13	Evotec Se Reaffirms Earnings Guidance for the Full-Year 2026	CI
08-06	Evotec, Odyssey Therapeutics Partner to Develop Autoimmune, Inflammatory Disease Treatments	MT
08-06	Evotec, Odyssey Therapeutics Team Up on Autoimmune, Inflammatory Disease Treatment Research	MT
08-06	Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases	EQ
08-06	Evotec : and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases	PU
08-03	Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168	CI
08-03	Niagen Bioscience, Evotec to Advance Preclinical Development of NB4168	MT
07-16	Berenberg Downgrades Evotec to Hold From Buy, Cuts Price Target to EUR3.60 From EUR9.40	MT
07-16	EVOTEC : Deutsche Bank reaffirms its Neutral rating	ZD
07-16	EVOTEC : Reduced to Neutral by Berenberg	ZD
07-16	Berenberg downgrades Evotec to 'Hold', target cut to €3.60	DP
07-15	Evotec Shares Fall After TD Cowen Downgrade	MT